Global Recombinant Erythropoietin Drugs Market Growth 2023-2029

Global Recombinant Erythropoietin Drugs Market Growth 2023-2029

Erythropoietin (EPO), also known as haematopoietin or haemopoietin, is a glycoprotein cytokine secreted by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow. Low levels of EPO (around 10 mU/mL) are constantly secreted sufficient to compensate for normal red blood cell turnover. Common causes of cellular hypoxia resulting in elevated levels of EPO (up to 10 000 mU/mL) include any anemia, and hypoxemia due to chronic lung disease.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with the peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. Liver production predominates in the fetal and perinatal period; renal production predominates in adulthood. It is homologous with thrombopoietin.

LPI (LP Information)' newest research report, the “Recombinant Erythropoietin Drugs Industry Forecast” looks at past sales and reviews total world Recombinant Erythropoietin Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Erythropoietin Drugs sales for 2023 through 2029. With Recombinant Erythropoietin Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Erythropoietin Drugs industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Erythropoietin Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Erythropoietin Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Recombinant Erythropoietin Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Erythropoietin Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Erythropoietin Drugs.

The global Recombinant Erythropoietin Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Recombinant Erythropoietin Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Recombinant Erythropoietin Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Recombinant Erythropoietin Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Recombinant Erythropoietin Drugs players cover Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Roche, 3SBio Group, Celltrion, Inc, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd and LG Life Sciences Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Erythropoietin Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
rhEPO
Erythropoiesis-Stimulating Agents (ESA)

Segmentation by application
Chronic Kidney Disease
Cancer Related Anemia
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Roche
3SBio Group
Celltrion, Inc
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
LG Life Sciences Ltd
Biocon Limited
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Dr. Reddy's Laboratories Ltd

Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Erythropoietin Drugs market?

What factors are driving Recombinant Erythropoietin Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Erythropoietin Drugs market opportunities vary by end market size?

How does Recombinant Erythropoietin Drugs break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.